Amgen Inc. buy Royal Bank of Canada
Start price
26.09.24
/
50%
€284.10
Target price
26.09.25
€324.86
Performance (%)
-17.65%
End price
27.09.25
€233.95
Summary
This prediction ended on 27.09.25 with a price of €233.95. The price of Amgen Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -17.65%. Royal_Bank_of_Canada has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. Dividends of €9.15 are taken into consideration when calculating the performance. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Amgen Inc. | -1.185% | -1.185% | 8.681% |
| iShares Core DAX® | 1,30 % | -1,39 % | 12,26 % |
| iShares Nasdaq 100 | 0,61 % | -4,17 % | 1,69 % |
| iShares Nikkei 225® | 8,77 % | 9,78 % | 30,04 % |
| iShares S&P 500 | 0,25 % | -2,30 % | 0,79 % |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Amgen Inc. diskutieren
Amgen Inc. (NASDAQ: AMGN) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $362.00 price target on the stock.
Ratings data for AMGN provided by MarketBeat
In the thread Trading Amgen Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten